Yi Zhang, MD degree, Director, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University / Academic Vice President, Zhengzhou University School of Medical Sciences / Director, Zhongyuan Cellular and Immunotherapy Laboratory, Henan Province. Prof. Zhang is a world-renowned leader in the area of genetically engineered cell therapy. His research has resulted in a number of genetically engineered cell therapy technological achievements with independent intellectual property rights. He has successfully converted 7 patents, with a transfer amount of more than 80 million yuan. Based on the innovative technology, he has hosted over 52 clinical trials on the application of new cell therapies in malignant tumors as the main PI. Among these, 29 clinical trials are for solid tumors, with the total number ranked first worldwide. Prof. Zhang has been recognized both in China and internationally for his significant contributions in overcoming bottlenecks in cell therapy and promoting the technological translation and clinical application of cell therapy achievements worldwide. He has conducted 35 years of research centered on basic research, clinical translation and clinical treatment of cellular therapy technology at renowned institutions in Belgium, the United States and China. He has published 270 SCI articles, including 11 ESI top 1% highly cited papers, with more than 14 000 citations. H dex:62. He has applied for 39 invention patents and 16 were authorized. He has presided over more than 50 projects at NIH and national levels, with the fund of 60 million RMB. Prof. Yi Zhang serves as an associate editor or editorial board member of J Hematol Oncol, Biomarker Research, Front. Cell Dev. Biol., Asia Pac J Clin Nutr., Cancer Control, Front Oncol. Chinese Journal of Immunology and Chinese Journal of Tumor Biotherapy. He also serves as a reviewer for dozens of journals such as Clinical Cancer Research, Cancer Research, Journal of Immunology, Cancer Letters, etc., and has reviewed more than thousands of manuscripts. Prof. Zhang is one of the world's top 100,000 scientists and a practitioner of innovative translational technologies in the field of tumor immunotherapy. As the chief scientist of the national key research and development program, he has made outstanding contributions to the new theory of the key mechanism affecting the efficacy of immunotherapy, and has been widely recognized by domestic and foreign peers. He has led the development and application of a number of original innovative technologies for tumor immunotherapy, which has greatly improved the immunotherapy efficacy of tumor patients and promoted the development of tumor immunotherapy. Prof. Yi Zhang has conducted in-depth research on the interaction between the tumor microenvironment and the immune system, focusing on the research, development and application of a variety of cell therapy technologies. He focuses on stimulating the team's innovative thinking and collaborative spirit to promote the development of scientific innovation and clinical application. He is good at managing the team, clarifying the responsibilities and division of labor among team members, establishing a good team communication and collaboration mechanism, and promoting the stable development of the team and the output of innovative results. He has an innovative mindset and is able to propose novel solutions and research ideas to promote breakthroughs in scientific research and innovative results. Prof. Zhang Yi loves reading, hiking and traveling.